Oncolytic virus · Kills target cells · developed by Oncolytics Biotech
Pelareorep is an oncolytic serotype 3 Dearing strain reovirus, a double-stranded RNA virus. It replicates in cancer cells with an activated Ras pathway, causing their death and releasing progeny virus to infect surrounding tumor cells, and it triggers innate and adaptive immune killing of tumor cells. It is studied in breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, prostate cancer and plasma cell myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01166542 | Phase 3 | Carcinoma, Squamous Cell of the Head and Neck | Completed | ONCY |
| NCT04215146 | Phase 2 | Breast Cancer Metastatic | Active not recruiting | ONCY |
| NCT01619813 | Phase 2 | Prostate Cancer | Completed | ONCY |
| NCT01708993 | Phase 2 | Non Small Cell Lung Cancer | Completed | ONCY |
| NCT00861627 | Phase 2 | Carcinoma, Non-small Cell Lung | Completed | ONCY |
| NCT05519059 | Phase 1 | Advanced or Metastatic Breast Cancer | Completed | ANL |
| NCT02514382 | Phase 1 | Recurrent Plasma Cell Myeloma | Completed | ONCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast Cancer MetastaticAdvanced or Metastatic Breast CancerCarcinoma, Non-small Cell LungCarcinoma, Squamous Cell of the Head and NeckNon Small Cell Lung CancerProstate CancerRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Updated Oct 11, 2026. Something wrong or missing? Report it on the ONCY page.
See ONCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONCY catalysts and pipeline →